The CPS (which assesses the number of PD-L1-positive tumour, lymphocytic and macrophage cells in relation to total tumour cells) [36] has been identified as a predictive biomarker of higher overall response rate (ORR) to pembrolizumab in mixed histology epithelial ovarian cancers. Here, CD274 is linked to ovarian carcinoma.